Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Janina Niggenaber"'
Autor:
Tobias Grabe, Kirujan Jeyakumar, Janina Niggenaber, Tom Schulz, Sandra Koska, Silke Kleinbölting, Michael Edmund Beck, Matthias P. Müller, Daniel Rauh
Publikováno v:
ACS Medicinal Chemistry Letters. 14:591-598
Autor:
Jonas Lategahn, Hannah L. Tumbrink, Carsten Schultz-Fademrecht, Alena Heimsoeth, Lisa Werr, Janina Niggenaber, Marina Keul, Fatma Parmaksiz, Matthias Baumann, Sascha Menninger, Eldar Zent, Ina Landel, Jörn Weisner, Kirujan Jeyakumar, Leonie Heyden, Nicole Russ, Fabienne Müller, Carina Lorenz, Johannes Brägelmann, Inga Spille, Tobias Grabe, Matthias P. Müller, Johannes M. Heuckmann, Bert M. Klebl, Peter Nussbaumer, Martin L. Sos, Daniel Rauh
Publikováno v:
Journal of Medicinal Chemistry. 65:6643-6655
Despite the clinical efficacy of epidermal growth factor receptor (EGFR) inhibitors, a subset of patients with non-small cell lung cancer displays insertion mutations in exon20 in EGFR and Her2 with limited treatment options. Here, we present the dev
Autor:
Daniel Rauh, Matthias P. Müller, Jonas Lategahn, Tobias Grabe, Janina Niggenaber, Leonie Heyden
Publikováno v:
ACS Med Chem Lett
[Image: see text] Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) and currently the gold-standard for the treatment of patients suffering from non-small cell lung cancer (NSCLC) harboring T790M-mutated epidermal growth factor recept
Autor:
Philip Klövekorn, Jonas Lategahn, Willem A. L. van Otterlo, Julia Hardick, Tobias Grabe, Daniel Rauh, Luke Hodson, Matthias P. Müller, Tonia Kirschner, Kirujan Jeyakumar, Matthias Baumann, Julia Ketzer, Sebastian Bauer, Susanne Terheyden, Janina Niggenaber, Christian Becker, Anke Unger, Hannah L. Tumbrink, Jörn Weisner, Marina Keul
Publikováno v:
Journal of Medicinal Chemistry. 63:11725-11755
Mutated or amplified Her2 serves as a driver of non-small cell lung cancer or mediates resistance toward the inhibition of its family member epidermal growth factor receptor with small-molecule inhibitors. To date, small-molecule inhibitors targeting
Publikováno v:
Journal of Medicinal Chemistry. 63:40-51
The ErbB receptor tyrosine kinase family members EGFR (epidermal growth factor receptor) and Her2 are among the prominent mutated oncogenic drivers of non-small cell lung cancer (NSCLC). Their importance in proliferation, apoptosis, and cell death ul
Autor:
Janina Niggenaber, Matthias Baumann, Sebastian Bauer, Heiko Muller, Tobias Grabe, Jan G. Hengstler, Marina Keul, Luke Hodson, Georgia Günther, Anke Unger, Bernhard Blank-Landeshammer, Daniel Rauh, Alena Heimsoeth, Hannah L. Tumbrink, Julia Ketzer, Christopher Golz, Matthias P. Müller, René P. Zahedi, Carsten Strohmann, Wolf Hiller, Julian Engel, Willem A. L. van Otterlo, Julia Hardick, Philip Klövekorn, Jonas Lategahn, Maren Flaßhoff, Laxmikanth Kollipara, Carsten Schultz-Fademrecht, Thomas Mühlenberg
Publikováno v:
Chemical science, 10:10789
Chemical Science
Chemical Science
We present inhibitors of drug resistant mutants of EGFR including T790M and C797S. In addition, we present the first X-ray crystal structures of covalent inhibitors in complex with C797S-mutated EGFR to gain insight into their binding mode.
Prec
Prec
Publikováno v:
Journal of medicinal chemistry. 63(1)
The ErbB receptor tyrosine kinase family members EGFR (epidermal growth factor receptor) and Her2 are among the prominent mutated oncogenic drivers of non-small cell lung cancer (NSCLC). Their importance in proliferation, apoptosis, and cell death ul
Autor:
Janina Niggenaber, Martin L. Sos, Matthias Baumann, Roman K. Thomas, Johannes M. Heuckmann, Carsten Schultz-Fademrecht, Jonas Lategahn, Hannah L. Tumbrink, Carsten Degenhart, Lisa Hanna Werr, Marina Keul, Daniel Rauh, Bert Klebl, Alena Heimsoeth, Sascha Menninger
Publikováno v:
Journal of Clinical Oncology. 37:e14718-e14718
e14718 Background: The majority of EGFR mutant tumors can be effectively treated with targeted drugs. Lung adenocarcinoma patients with EGFR Ex20 insertion mutations, however, lack safe and potent treatment options. These genetic alterations share ho